Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 11
Breast cancer risk in a rapidly aging population: advances and approaches to study the aging tissue microenvironment
Authors Greco SJ
Received 9 January 2019
Accepted for publication 15 January 2019
Published 19 February 2019 Volume 2019:11 Pages 111—113
DOI https://doi.org/10.2147/BCTT.S200949
Checked for plagiarism Yes
Editor who approved publication: Professor Pranela Rameshwar
Steven J Greco
Department of Medicine, Division of Hematology and Oncology, Rutgers-New Jersey Medical School, Newark, NJ, USA
Aging is the predominant risk factor for most chronic diseases, and is the primary cause of morbidity and mortality in the developed world. The rapidly increasing rate of global aging poses significant economic concern to the current health care model. A better understanding of the biology of aging is necessary to yield new approaches that extend the human “health span” and delay the onset of age-related disease. These approaches would address the underlying mechanisms of disease, rather than treat their symptoms individually.
Acknowledgments
The work was supported by an award given by the US Department of Defense, W81XWH-11-1-0276. This work was supported by a grant from the US Department of Defense.
Disclosure
The author reports no conflicts of interest in this work.
References
Karuturi M, VanderWalde N, Muss H. Approach and management of breast cancer in the elderly. Clin Geriatr Med. 2016;32(1):133–153. | ||
Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol. 2017;44:72–82. | ||
Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793–802. | ||
Smith BD, Jiang J, McLaughlin SS, et al. Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol. 2011;29(35):4647–4653. | ||
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371(9606):29–40. | ||
Lyratzopoulos G, Abel GA, Brown CH, et al. Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer. Ann Oncol. 2013;24(3):843–850. | ||
Owusu C, Lash TL, Silliman RA. Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat. 2007;102(2):227–236. | ||
Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550–556. | ||
Daidone MG, Coradini D, Martelli G, Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003;45(3):313–325. | ||
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. | ||
Shiozawa Y, Eber MR, Berry JE, Taichman RS. Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. Bonekey Rep. 2015;4:689. | ||
Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13(6):227. | ||
Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24(3):511–520. | ||
Emens LA, Kok M, Ojalvo LS. Targeting the programmed cell death-1 pathway in breast and ovarian cancer. Curr Opin Obstet Gynecol. 2016;28(2):142–147. | ||
Bonafè M, Storci G, Franceschi C. Inflamm-aging of the stem cell niche: breast cancer as a paradigmatic example: breakdown of the multi-shell cytokine network fuels cancer in aged people. Bioessays. 2012;34(1):40–49. | ||
Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–129. | ||
Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12(12):1597–1611. | ||
Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology. 2015;29(5):375–385. | ||
Chiriac VF, Baban A, Dumitrascu DL. Psychological stress and breast cancer incidence: a systematic review. Clujul Med. 2018;91(1):18–26. | ||
Straub RH, Cutolo M. Psychoneuroimmunology-developments in stress research. Wien Med Wochenschr. 2018;168(3–4):76–84. | ||
Crone M, Hallman K, Lloyd V, et al. The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells. Breast Cancer (Dove Med Press). In press 2019. | ||
Ozdemir BZ, Goodin JB, Bodenner DL. Breast cancer prevention in older women: an algorithm to choose an optimal preventive agent. Breast Cancer (Dove Med Press). In press 2019. | ||
Tremmel E, Hofmann S, Kuhn C, et al. Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. Breast Cancer (Dove Med Press). In press 2019. | ||
Ayoub NM, Al-Shami KM, Yaghan RJ. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer (Dove Med Press). 2019;11:53–69. | ||
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Breast Cancer: Targets and Therapy ‘Editorial’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Breast Cancer: Targets and Therapy editors. While all reasonable steps have been taken to confirm the content of each Editorial, Dove Medical Press accepts no liability in respect of the content of any Editorial, nor is it responsible for the content and accuracy of any Editorial. |
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.